GlassScriptPhysician profile
Jeffery S Kelley
NPI 1659334126
$3,474.53
in general payments reported to CMS, 2019-2025
28 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $303 · 2020: $423 · 2021: $714 · 2022: $486 · 2023: $379 · 2024: $593 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $924.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $396.12 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $361.61 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $312.42 | 2019-2022 | |
| Dexcom, INC. | $301.19 | 2022-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $185.68 | 2019-2025 | Airsupra |
| Pfizer INC. | $157.51 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $115.33 | 2019-2022 | |
| Allergan, INC. | $85.34 | 2019-2020 | |
| Lilly USA, LLC | $80.77 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $79.58 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $74.55 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $51.47 | 2021-2022 | |
| Esperion Therapeutics, INC. | $48.94 | 2021 | |
| Philips North America LLC | $42.72 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $40.43 | 2020-2021 | |
| Shield Therapeutics INC | $24.16 | 2025 | |
| Phathom Pharmaceuticals, INC. | $23.40 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $23.04 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $21.37 | 2025 | Austedo Xr |
| Azurity Pharmaceuticals, INC. | $21.28 | 2025 | |
| Inspire Medical Systems, INC. | $16.69 | 2025 | Inspire |
| Amgen INC. | $16.47 | 2025 | Repatha |
| Corcept Therapeutics | $16.15 | 2024 | Korlym |
| Zyla Life Sciences, INC. | $15.87 | 2019 | |
| Ardelyx, INC. | $14.71 | 2025 | Ibsrela |
| Jazz Pharmaceuticals INC. | $11.70 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.